TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05143060

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cereal powder
Description: Eat or drink oral glucose (reference) the valley of fiber powder upgrade formula, perfect meals, by extraction shu cereal bars, light appearance suits (by extraction shu compound dietary fiber powder, feeding combination 1:1) and 17 extraction enzyme 6 kinds of food respectively in different periods.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pure glucose powder
Description: Pure glucose powder
Study: NCT05910840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Support-t
Description: Support-t plus usual diabetes care for 18 months
Study: NCT04518449

Intervention type: PROCEDURE
Intervention: medial border along the left side of SMA
Description: to place the medial border along the left side of SMA in laparoscopic D3 lymphadenectomy for right colon cancer

Intervention type: PROCEDURE
Intervention: medial border along the left side of SMV
Description: to place the medial border along the left side of SMV in laparoscopic D3 lymphadenectomy for right colon cancer
Study: NCT05643859

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Fiber
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proctoscopy or anoscopy with Biopsy
Description: Undergo proctoscopy or anoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Undergo Colonoscopy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04724239

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab
Description: 200mg IV on Day 1 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg IV on Day 1 Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chidamide
Description: 30mg PO BIW each 3-week cycle
Study: NCT06035094

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention to improve overall Brain Health
Description: During each exercise session, the participant will be assigned to the HIIT or MIT exercise group and asked to ride the stationary bicycle for approximately 30-40 minutes, while wearing the heart rate monitor and recording the session on their smart phone application. For each exercise session, the Polar Beat application will record the time in each of four intensity zones. The participant will receive training on how to use the outlined schedule during the initial supervised training session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention to improve overall Brain Health
Description: During each exercise session, the participant will be assigned to the HIIT or MIT exercise group and asked to ride the stationary bicycle for approximately 30-40 minutes, while wearing the heart rate monitor and recording the session on their smart phone application. For each exercise session, the Polar Beat application will record the time in each of four intensity zones. The participant will receive training on how to use the outlined schedule during the initial supervised training session.
Study: NCT04724239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 30mg PO BIW each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI305
Description: 7.5mg/kg IV on Day 1 Q3W
Study: NCT06273553

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RG002 injection
Description: In Part A, there are three dose cohorts that are 25µg,75µg and 150µg. In Part B, there will 1 or 2 dose levels according to the results of Part A. All subjects will receive a total of three RG002 Injections, administered intramuscularly at assigned dose level, with a dosing frequency of every 2 weeks (D1, D15, and D29).
Study: NCT05422248

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Series Topical Oxygen Therapy
Description: Standard care provided to the whole wound followed by intervention device care to the whole wound.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paired Topical Oxygen Therapy
Description: Care provided to one portion of wound by intervention device and standard care to remaining portion of wound.
Study: NCT05746546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine patch
Description: Participants will wear nicotine transdermal patches daily for 12-15 weeks. Participants will apply a study patch each morning and remove at bedtime. Active dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
Study: NCT06035094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention to improve overall Brain Health
Description: During each exercise session, the participant will be assigned to the HIIT or MIT exercise group and asked to ride the stationary bicycle for approximately 30-40 minutes, while wearing the heart rate monitor and recording the session on their smart phone application. For each exercise session, the Polar Beat application will record the time in each of four intensity zones. The participant will receive training on how to use the outlined schedule during the initial supervised training session.
Study: NCT05495945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity focused ultrasound pulsation (LIFUP)
Description: LIFUP will be used to stimulate specific brain regions and assess their causal involvement in the control of conscious state and contents.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity focused ultrasound pulsation (LIFUP)
Description: LIFUP will be used to stimulate specific brain regions and assess their causal involvement in the control of conscious state and contents.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity focused ultrasound pulsation (LIFUP)
Description: LIFUP will be used to stimulate specific brain regions and assess their causal involvement in the control of conscious state and contents.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging (fMRI) using Propofol
Description: Propofol will be administered by intravenous infusion. All anesthesia equipment, supplies, and drugs will be provided by anesthesiologists from the University of Michigan Health System. The researchers will manually control the infusion of propofol to achieve target effect-site concentrations

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging (fMRI) using Propofol
Description: Propofol will be administered by intravenous infusion. All anesthesia equipment, supplies, and drugs will be provided by anesthesiologists from the University of Michigan Health System. The researchers will manually control the infusion of propofol to achieve target effect-site concentrations

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging (fMRI) using Propofol
Description: Propofol will be administered by intravenous infusion. All anesthesia equipment, supplies, and drugs will be provided by anesthesiologists from the University of Michigan Health System. The researchers will manually control the infusion of propofol to achieve target effect-site concentrations

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Functional Magnetic Resonance Imaging (fMRI) using Propofol
Description: Propofol will be administered by intravenous infusion. All anesthesia equipment, supplies, and drugs will be provided by anesthesiologists from the University of Michigan Health System. The researchers will manually control the infusion of propofol to achieve target effect-site concentrations
Study: NCT04617457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA)
Description: preoperative chemotherapy
Study: NCT05563454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2395840
Description: Administration of dosage form 1 under diet 1 condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2395840
Description: Administration of dosage form 1 under diet 1 condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2395840
Description: Administration of dosage form 1 under diet 1 condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2395840
Description: Administration of dosage form 1 under diet 1 condition
Study: NCT05667090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Oral supplementaiton of 576,000 IU once a week of vitamin D3 for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral supplementaiton of placebo once a week for 4 weeks
Study: NCT06467266

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Acute Haemodynamic Study
Description: Multisite temporary pacing
Study: NCT05625477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNM002 (low dose)
Description: Single dose of TNM002 administered by intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNM002 (medium dose)
Description: Single dose of TNM002 administered by intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNM002 (high dose)
Description: Single dose of TNM002 administered by intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HTIG
Description: Single dose of HTIG administered by intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo administered by intramuscular injection
Study: NCT05208216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Geko device
Description: A small battery powered device that provides neuromuscular stimulation to the muscles of the lower leg to enhance venous return from the leg and reduce the risk of patient developing VTE.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flowtron DVT
Description: A pneumatically powered pair of calf boots device that intermittently compress the muscles of the lower leg to enhance venous return from the leg and reduce the risk of patient developing VTE.
Study: NCT04765488

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WashIn /WashOut
Description: According Wash In / WashOut procedure in study group we stop the supply of sevoflurane to the first signs of awakening and record the level of sevoflurane , then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and stop the supply of sevoflurane to the first signs of awakening again, then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and finally ( the third time) stop supplying sevoflurane and extubate patient after recovery of muscle tone, spontaneous breathing and consciousness.
Study: NCT05580224

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation is performed for peripherally located small hepatocellular carcinoma using combined energy delivery mode and triple cooled-wet electrodes. One of three electrodes is placed across the 4th or 5th portal vein branches near the target tumor which enables anatomical ablation of tumor.
Study: NCT05637645

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Midline Approach
Description: In the midline approach, the spinal approach to the intrathecal space is midline with a straight line shot. After infiltration with lidocaine, the spinal needle is introduced into the skin, angled slightly cephalic. The needle traverses the skin, followed by subcutaneous fat. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paramedian Approach
Description: The paramedian approach involves inserting the spinal needle 1 cm away from the midline in medial direction. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Taylors approach
Description: his arm will have the procedure of spinal anesthetic performed via 'Taylor's approach' which is a paramedian approach to interspace L5 - S1. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
Study: NCT04717128

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breastfeeding Skills Workshop
Description: Participants will complete the standardized patient-led breastfeeding skills workshop where they will learn breast massage techniques to alleviate plugged ducts and engorgement, hand expression of breast milk, effective breast pump use, and newborn positioning and attachment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding Skills Workshop
Description: Participants will complete the standardized patient-led breastfeeding skills workshop where they will learn breast massage techniques to alleviate plugged ducts and engorgement, hand expression of breast milk, effective breast pump use, and newborn positioning and attachment.
Study: NCT05525819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control group
Description: The cases will be subjected to spinal anesthesia with a 3 ml volume (2.5 ml of hyperbaric bupivacaine 10 mg in addition to 0.5 normal saline). 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal group
Description: The cases will be subjected to the same anesthetic mixture as controls with adding dexmedetomidine 5 μg in the saline component. 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous group
Description: The intravenous group will receive 2.5 ml of hyperbaric bupivacaine (10 mg), in addition to intravenous dexmedetomidine, which will be started at 1 μg/kg loading dose diluted in 50 ml saline administered within 10 min, followed by maintenance at a 0.4 μg/kg/h dose diluted in 200 ml saline till the end of the procedure.
Study: NCT05410652

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of fecal samples with diagnostic kit
Description: The 23S rRNA mutation site of clarithromycin and gyrA mutation site of levofloxacin were detected by Helicobacter Pylori fecal Gene Mutation Detection Kit.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sanger Sequencing group
Description: Detection of gyrA and 23S rRNA mutations in H. pylori isolated from Gastric Mucosa by Sanger Sequencing

Intervention type: DIAGNOSTIC_TEST
Intervention: Bacterial culture and drug sensitivity test of gastric mucosa samples
Description: First, a sample of the patient's gastric mucosa will be obtained through gastroscopy. Then, Helicobacter pylori culture and drug sensitivity test can be carried out. Finally, the resistance data of Helicobacter pylori to clarithromycin and levofloxacin will be obtained.
Study: NCT04877262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weight maintenance diet (WMD)
Description: A diet meeting the participant's weight maintenance energy needs will be provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weight maintenance diet (WMD)
Description: A diet meeting the participant's weight maintenance energy needs will be provided.
Study: NCT06380478

Intervention type: DEVICE
Intervention: aspicio Monofocal IOL
Description: A bi-aspheric monofocal IOL is implanted through preloaded IOL Delivery System in the capsular bag in the posterior chamber of the eye during cataract surgery
Study: NCT05835453

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whitening
Description: Two syringes of 10% carbamide peroxide bleaching gel will be provided for use with each type of tray. Volunteers will be instructed to use the whitening gel once a day for 2 hours, for 3 days per week with each tray, completing a total of 4 weeks of whitening procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whitening
Description: Two syringes of 10% carbamide peroxide bleaching gel will be provided for use with each type of tray. Volunteers will be instructed to use the whitening gel once a day for 2 hours, for 3 days per week with each tray, completing a total of 4 weeks of whitening procedure.
Study: NCT05353192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone
Description: Recombinant human growth hormone (15IU/5mg/3ml/bottle)，0.05 mg/kg/d by subcutaneous injection for 52 weeks
Study: NCT06263335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction Intervention
Description: During an eight-week intervention period, clients were to engage in mindfulness practices lasting between 45 minutes to an hour each session. The intervention would incorporate various components of the Mindfulness-Based Stress Reduction (MBSR) program, including mindfulness of the present moment, body scans, mindful eating, walking meditation, yoga exercises, and discussions on applying mindfulness to everyday experiences and stress management. Sessions would typically range from 30 to 90 minutes per week, with an additional full-day retreat session towards the end of the program. In addition to mindfulness practice, participants were to receive teachings on stress management and its application to interpersonal and daily life situations.
Study: NCT05041088

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProdromeNeuro Plasmalogen
Description: The product being investigated in this study is the ProdromeNeuro Omega 3 oil nutritional supplement. This product contains naturally occurring fatty acids in higher concentrations than similar products that are commercially available. The purpose of this research study is to better understand the effects of ProdromeNeuro Omega-3 nutritional supplementation among participants with age-related cognitive decline.
Study: NCT04619823

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample collection
Description: Blood sample collection Mosquito collection at home
Study: NCT05487209

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI,SCC-Ag
Description: Magnetic Resonance Imaging examination,serum squamous cells carcinoma antigen
Study: NCT06086184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT group therapy
Description: Participation in four sessions of the inpatient Compass Group and eight sessions of the inpatient Here-and-Now Group. This should be completed within four weeks and may be completed within six weeks in exceptional cases. The groups are designed as a semi-open group with one therapist and one cotherapist each and are integrated into the existing therapy plan.
Study: NCT06086535

Intervention type: PROCEDURE
Intervention: Intercostal nerve cryoanalgesia vs BRILMA blockade
Description: For BRILMA block, 0.4 ml/kg of 0.3% ropivacaine will be injected and a catheter will be placed on the 4th intercostal space after surgery. For intercostal nerve cryoanalgesia an external cryogenizer system will be used during surgery

Intervention type: PROCEDURE
Intervention: Intercostal nerve cryoanalgesia vs BRILMA blockade
Description: For BRILMA block, 0.4 ml/kg of 0.3% ropivacaine will be injected and a catheter will be placed on the 4th intercostal space after surgery. For intercostal nerve cryoanalgesia an external cryogenizer system will be used during surgery
Study: NCT06211816

Intervention type: OTHER
Group type: OTHER
Intervention: communication strategy
Description: an intensive communication strategy on end-of-life practice was implemented, based on a framework developed by the International Delphi Conference.
Study: NCT06317701

Intervention type: DEVICE
Intervention: Hypoglossal Nerve Stimulation (HGNS)
Description: Alternative therapy for Obstructive Sleep Apnea
Study: NCT06214429

Intervention type: DIAGNOSTIC_TEST
Intervention: Vascular Ultrasound
Description: Complete vascular ultrasound routine in B mode, color mode and Doppler.

Intervention type: DIAGNOSTIC_TEST
Intervention: Shear Wave Elastography
Description: Vascular ultrasound assisted shear wave elastography of the atherosclerotic plaque.

Intervention type: DIAGNOSTIC_TEST
Intervention: Greyscale Median
Description: Vascular ultrasound assisted assessment of the plaque in B mode. The plaque image will be post-processed for the histogram median value for the plaque area.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Assessment of the plaque and carotid residual lumen by magnetic resonance.

Intervention type: DIAGNOSTIC_TEST
Intervention: Histopathology
Description: Histopathology findings for patients that undergo carotid endarterectomy.
Study: NCT06382623

Intervention type: PROCEDURE
Intervention: The percutaneous A1 pulley release
Description: Ultrasound-guided percutaneous pulley release is a procedure aimed at loosening the pulley using various cutting instruments or hypodermic needles under ultrasound guidance.

Intervention type: OTHER
Intervention: The peritendinous Betamethasone group
Description: USG-guided injection of corticosteroid between the A1 pulley and the flexor tendon sheath.
Study: NCT05483010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin is commercially available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin is commercially available.